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represented less than 0.5% of Medicaid spending in 2013 so cost-containment strate-
gies targeting triptans could not have had a large impact on the Medicaid budget. 
The large increase in triptan prescriptions in 2010 is suggestive of reduced access to 
these medications for many years by Medicaid beneficiaries. Even prior to generic 
sumatriptan entry in the market, sumatriptan held the highest market share in 
Medicaid. This finding is not necessarily explained by superior safety or effective-
ness relative to the other triptans.
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OBJECTIVES: Specialty tiers under Medicare Part D can require a coinsurance of 
up to 33% for drugs that cost $600 per month or more. This study is the first to 
examine the impact of such high cost sharing on use of disease modifying thera-
pies (DMTs) in Medicare beneficiaries with multiple sclerosis (MS). METHODS: 
Using the 2007-2010 5% Medicare files we identified MS patients (ICD-9-CM 340.
xx) with continuous fee-for-service Part D coverage and potential eligibility for 
DMTs in each year based on evidence of disease activity (any DMT use or relapse 
in previous year [N= 3,975]). Outcomes included any fill, adherence (proportion of 
days covered> = 0.80), and continuous 30-day gap for Part D-covered DMTs in the 
initial coverage limit (ICL) period wherein patients not receiving low-income sub-
sidies (non-LIS) faced specialty tiers (25%-33% coinsurance). Similar outcomes for 
Part B-covered and all DMTs allowed examination of impact on substitution and 
overall use, respectively. LIS patients who faced minimal cost sharing ($3-$5 copay) 
in the Part D ICL period served as controls. Logistic regressions with formulary 
fixed-effects compared outcomes across non-LIS and LIS patients with active MS 
facing the same formulary and utilization management tools (but different cost 
sharing levels) while controlling for a series of patient confounders. RESULTS: In 
comparison to LIS patients, non-LIS patients were significantly less likely to use 
Part D DMTs (odds ratios for any fill= 0.36; adherence= 0.42; gap= 2.54,p< 0.001 for 
all ORs). Non-LIS patients were more likely to use Part B DMTs; however, the higher 
use of Part B DMTs did not fully compensate for the lower use of Part D DMTs. As a 
result, non-LIS patients had lower use of any DMTs during the ICL period (ORs for 
any fill= 1.73, adherence = 0.69; gap OR= 1.68,p< 0.05 for all ORs). CONCLUSIONS: 
Part D specialty tier cost sharing was associated with lower likelihood of filling, 
adherence, and continuation of DMTs.
PND68
treNDS aSSociateD with imPlemeNtiNg aND liftiNg a SteP theraPy 
Policy for PregaBaliN iN the humaNa meDicare PoPulatioN: aN 
iNterruPteD time SerieS aNalySiS
Null K.D.1, Moll K.1, Cappelleri J.C.2, Sadosky A.3, Parsons B.3, Pasquale M.K.1
1Comprehensive Health Insights, Louisville, KY, USA, 2Pfizer Inc, Groton, CT, USA, 3Pfizer Inc, New 
York, NY, USA
OBJECTIVES: Humana implemented a step therapy (ST) policy on pregabalin 
for Medicare and commercial plans effective January 2009, and lifted the policy 
for Medicare plans only in April 2013. This study examined the impact of the 
(ST) on pregabalin utilization and therapeutic alternatives, as well as medical 
expenditures for diabetic peripheral neuropathy (DPN), post herpetic neuralgia 
(PHN), and fibromyalgia (FM). METHODS: An interrupted time series design exam-
ined monthly pharmacy and medical claims during January 2007 – April 2014. 
Segmented regression analyses allowed for two change points: January 2009 and 
April 2013 accounting for policy implementation and lift, respectively. Results 
were reported as the average number of claims per 100,000 members per month 
(P100KMPM) for time trend and level change following ST changes. RESULTS: 
The ST implementation resulted in a statistically significant decrease in prega-
balin use by Medicare members, while its lift resulted in a marginally significant 
increase (level change after ST: -198.2 P100KMPM [P< .001]; level change after lift: 
50.5 P100KMPM [P= .072]) in pregabalin use by Medicare members. There was no 
change over time after the ST implementation or lift. As a comparator, the level 
change for commercial members was -107.3 P100KMPM (P< .001) but remained flat 
following the lift (P= .730). Utilization of anticonvulsants in Medicare, which con-
tains the ST prerequisite therapy gabapentin, saw a consistent increase following 
the implementation of the pregabalin ST (trend change after ST: 11.2 P100KMPM 
[P= 0.032]; level change after lift: 289.5 P100KMPM [P< 0.001]; and trend change 
after lift: -22.1 P100KMPM [P= .002]). Medical expenditures for DPN, PHN, and FM 
among the Medicare population increased throughout the study period, but did 
not appear to be impacted by the pregabalin ST (P= .062, P= .361, P= .778 for DPN, FM 
and PHN respectively for level change following implementation). CONCLUSIONS: 
Humana’s ST edit policy has shifted members away from pregabalin but without 
significant impact on disease-related medical costs.
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OBJECTIVES: Seizure clusters, defined as multiple distinct seizures that occur over a 
24-hour period, are serious medical events that may progress to prolonged seizures 
and status epilepticus. In this retrospective chart review, use of rescue medication, 
associated healthcare resource utilization, and costs of seizure clusters were evalu-
ated. METHODS: An online, retrospective chart review of patients with epilepsy 
and seizure clusters was conducted among 186 US neurologists. Adults (≥ 18 years 
old) who were diagnosed with seizure clusters at least 12 months prior to chart 
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OBJECTIVES: Multiple sclerosis (MS) is a chronic neurological disease associated 
with substantial clinical and socioeconomic burden. MS patients experience increas-
ing levels of disability as their disease progresses and this can represent a major 
cause for reduced work capacity. This study evaluates work productivity using Work 
Productivity and Activity Impairment (WPAI) questionnaire for RRMS and SPMS 
patients across Europe. METHODS: Data were drawn from the Adelphi MS Disease 
Specific Programme, a cross-sectional study of 360 neurologists and 3641 patients 
in France, Germany, Italy, Spain, and the United Kingdom. Patient-reported data 
was available for 881 RRMS patients and 142 SPMS patients. Fisher’s Exact or Chi-
Squared (for categorical outcomes) and Mann-Whitney (for numerical outcomes) 
were used to determine differences between RRMS and SPMS patients. RESULTS: 
Compared with RRMS patients, SPMS patients differ significantly in employment 
status (p< 0.0001); SPMS patients are less likely to be employed in full-time (8.0% 
vs. 50.0 %), part time positions (16.8% vs. 17.8%) or be students (1.8% vs 7.9%), and 
are more likely to be unemployed (15.0% vs. 9.8%), unable to be employed (23.0% vs. 
4.0%), retired (23.0% vs 3.4%) or homemakers (12.4% vs 7.2%). Analyses for the WPAI 
questionnaire included 523 RRMS and 29 SPMS patients. Significant differences were 
observed between RRMS and SPMS patients in absenteeism (22.2% vs. 8.5%; p= 0.034), 
presenteeism (34.4% vs 23.4%; p= 0.021) and overall impairment (42.0% vs 25.7%; 
p= 0.004). SPMS patients have a higher mean percentage of daily activity impairment 
due to MS than RRMS patients (65.00% vs 34.56%; p< 0.0001). CONCLUSIONS: Across 
Europe, SPMS patients experience a higher burden of illness and significantly greater 
magnitude of reduced work productivity than RRMS patients. SPMS patients are less 
likely to be employed full-time, and for those that are employed, work and activity 
impairment are significantly greater in SPMS vs RRMS patients.
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OBJECTIVES: To describe the application and perceived utility of pharmacogenomic 
recommendations among physicians managing a cohort of Medicare patients’ 
chronic medical conditions. METHODS: From January 1 through April 30, 2013, 
genetic results were reviewed from Medicare patients. Demographic data included 
patients’ date of birth, age, ethnicity, gender, medication count, ICD-9-CM diagnosis 
codes, insurance information, and current medications. Patients’ physicians were 
provided with a standardized report, including CYP3A4, CYP3A5, CYP2D6, CYP2C19, 
CYP2C9, VKORC1, MTHFR1298, MTHFR677, Factor V, and Factor II genotypes, pheno-
types, and individualized clinical recommendations. Physicians’ responses to a sur-
vey regarding the use of the recommendations were then summarized. RESULTS: 
One hundred and ninety-five patients, with a mean age of 66 years (59% female) 
and an average of 8.7 medications were reviewed. Seventy-seven percent (144/187) 
of physicians’ responses indicated that the reports were received in a timely man-
ner and 99% (192/194) indicated that they were actionable and easy to understand. 
Forty-one percent (77/186) made a dosing change, 52% (99/192) a medication change, 
and 10% (14/137) a medication therapy duration change. Twenty-five percent (46/183) 
indicated that without the report, no changes would have been made, while 38% 
reflected that their clinical assessment alone would have led to therapy modifi-
cation. CONCLUSIONS: Despite timely receipt and ease of understanding, phy-
sicians appear reluctant to utilize pharmacogenomic recommendations from an 
outside source to make changes to medication dosing, regimen, or duration for 
their patients.
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OBJECTIVES: Following FDA approval of sumatriptan in December 1992, sumatriptan 
and subsequently-approved triptans quickly became first-line anti-migraine thera-
pies. The objective of this study was to describe utilization and reimbursement 
trends for triptans over the last two decades in U.S. Medicaid programs. METHODS: 
Using the national summary file for Medicaid outpatient drug utilization main-
tained by the Centers for Medicare and Medicaid Services, quarterly utilization 
and (pre-rebate) expenditure data from 1993-2013 were extracted for all triptans 
reimbursed for Medicaid beneficiaries. Because data were available at the national 
drug code level, data were collected separately for tablets (including orally disin-
tegrating tablets or ODTs), injections, and sprays. RESULTS: The total number of 
triptan prescriptions increased from 87,348 in 1993 to 1.2 million in 2013, with an 
almost doubling of prescriptions between 2010 and 2011, following the availability of 
a generic version of sumatriptan, which led to the loosening of Medicaid restrictions 
surrounding costly triptan use. In 2013, the share of Medicaid reimbursement ($95.9 
million in total) was 75.1% for tablets (including 18.0% for ODTs), 18.6% for injec-
tions, and 6.3% for sprays. In 2013, average reimbursement per prescription was $54 
for tablets, $246 for ODTs, $351 for injections, and $230 for sprays. From 1993-2013, 
sumatriptan was the most widely prescribed among the triptans, accounting for 
74.8% of all Medicaid prescriptions in 2013. CONCLUSIONS: Spending on triptans 
